Summary of Royal Philips Q4 and Full Year 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Performance::

Order intake increased by 7% year-on-year.

Comparable sales growth of 7%, broad-based across all segments.

Adjusted EBITDA margin improved by 160 basis points to 15.1%.

Net income rose to EUR 397 million, reflecting improved operations and lower tax charges.

Adjusted diluted earnings per share increased by 20% to EUR 0.60.

Free cash flow for Q4 was EUR 1.2 billion, down EUR 85 million year-over-year due to a tough comparison base.

Full Year 2025 Performance::

Order intake grew 6% for the year.

Comparable sales growth was 2.3%, in line with expectations.

Adjusted EBITDA margin increased by 80 basis points to 12.3%.

Total free cash flow reached EUR 512 million.

2Strategic Updates and Business Highlights

Business Segments::

Diagnosis & Treatment (D&T):: Comparable sales growth of 4% in Q4, with strong performance in Image-Guided Therapy (double-digit growth). Adjusted EBITDA margin declined slightly to 11.8%.

Connected Care:: Achieved 7% sales growth in Q4, with a margin expansion to 16.5%. Strong demand for monitoring and enterprise informatics solutions, particularly in North America.

Personal Health:: Sales grew 14% in Q4, with a margin of 23%, driven by strong demand for premium products and effective commercial execution.

Innovation and Partnerships::

Launched several new products, including a helium-free 3T MRI and AI-enabled solutions.

Expanded partnerships with major U.S. health systems, enhancing market presence.

3Forward Guidance and Outlook

2026 Expectations::

Anticipated comparable sales growth of 3% to 4.5%, with all business segments contributing.

Adjusted EBITDA margin expected to improve to 12.5% to 13%.

Free cash flow projected between EUR 1.3 billion and EUR 1.5 billion.

Continued focus on productivity with a new EUR 1.5 billion productivity program set for 2026-2028.

4Bad News, Challenges, or Points of Concern

Tariff Impact:: Anticipated net impact of EUR 250 million to EUR 300 million from tariffs in 2026, despite mitigation efforts.

China Market Caution:: While expecting stabilization, there are concerns regarding tender activities and competition affecting growth in the region.

Precision Diagnosis Segment:: Flat performance in Q4 raised questions about momentum going into 2026, especially given the higher exposure to China.

5Notable Q&A Insights

Order Intake Dynamics:: Management highlighted strong order intake momentum, particularly in North America, but acknowledged longer conversion cycles in D&T compared to Connected Care.

Margin Improvement Factors:: Management emphasized that gross margin improvements would continue despite tariff impacts, driven by innovation and productivity.

China Market Outlook:: Differentiated outlook between Personal Health and D&T, with cautious optimism for Personal Health but concerns about the health systems segment.

Q1 2026 Guidance:: Expected to start at the lower end of the growth range due to seasonality and tariff impacts, with a balanced growth profile anticipated throughout the year. This summary encapsulates the key financial metrics, strategic initiatives, and outlook for Philips while addressing challenges and insights from the Q&A session.